Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026 NEW YORK, NY /…
The GenAI-powered platform automates benefit verification, prior authorization, and payer follow-up to reduce treatment delays and manual burdenSAN FRANCISCO--(BUSINESS WIRE)--Develop…
MARLTON, N.J., Aug. 20, 2025 /PRNewswire/ -- Tribe Intensive NJ, a premier dual-diagnosis addiction treatment provider offering both partial hospitalization…
U.S. Senate Appropriations Report Further Validates Adial’s Therapeutic Approach and Promotes a More Contemporary Patient Focused Regulatory EnvironmentGLEN ALLEN, Va.,…
The Investment is part of BrainsWay’s ongoing strategy to acquire minority positions in leading U.S. mental health providers to help…
After a successful pilot, Dismas Charities partners with The Change Companies to bring individualized, digital-first programming to justice-involved individuals. CARSON…
Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4…
~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed,…
DEA Administrator Terrance Cole has also signaled a tough line: "Everybody knows my stance on marijuana after 30 plus years…
We're Out of Time Podcast Host & Addiction Recovery Expert Richard Taite Endorses Bereaved Parents' Nationwide, In-School Fentanyl Prevention Effort…